SUTRO BIOPHARMA, INC.

Sutro Biopharma reported a net loss of $38.5 million for Q2 2026, with revenue of $9.8 million. For the six months ended June 30, 2026, the net loss was $77.0 million on $24.4 million in revenue. The company completed a public offering in February 2026, raising $110.0 million, and had $164.3 million in unrestricted cash, cash equivalents, and marketable securities as of June 30, 2026, which is expected to fund operations for at least 12 months. These results follow significant restructuring plans in 2025 and a 1-for-10 reverse stock split.

Sutro Biopharma reported a net loss of $(38.5) million for Q2 2026, compared to $(11.5) million in Q2 2025, with revenue at $9.8 million. The company announced encouraging early clinical activity for STRO-004, its TF-targeting ADC, in a Phase 1 study, including partial responses and favorable tolerability. Sutro also highlighted pipeline progress, with STRO-006 expected to enter the clinic in Q3 2026 and STRO-227 on track for IND submission in 2026. The company maintains a strong balance sheet with $164.3 million in cash, supporting operations into at least Q2 2028.

Sutro Biopharma, Inc. reported a significant reduction in its net loss for the first quarter of 2026, decreasing to $38.5 million from $76.0 million in the prior year, primarily due to lower operating expenses following its 2025 restructuring plans. The company also successfully completed a public offering in February 2026, raising approximately $110.0 million in gross proceeds by selling 7.87 million shares of common stock. This capital raise substantially improved its cash position, with unrestricted cash, cash equivalents, and marketable securities increasing to $202.6 million, providing liquidity for at least 12 months, despite an accumulated deficit of over $1 billion.

Sutro Biopharma reported a net loss of $38.48 million for Q1 2026, an improvement from $75.97 million in Q1 2025, with revenue at $14.5 million. The company strengthened its balance sheet through a $110.0 million capital raise, boosting cash, cash equivalents, and marketable securities to $202.6 million, extending its cash runway into at least Q2 2028. Key pipeline programs, including STRO-004, STRO-006, and STRO-227, are progressing, with initial STRO-004 data expected mid-2026 and IND submissions for STRO-006 and STRO-227 planned for 2026.